Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Antiviral effects of selected nucleoside analogues against human parechoviruses A1 and A3.

Lanko K, Ma Y, Delang L, Mirabelli C, Neyts J.

Antiviral Res. 2018 Dec 12;162:51-53. doi: 10.1016/j.antiviral.2018.12.009. [Epub ahead of print]

2.

CCL20, a direct-acting pro-angiogenic chemokine induced by hepatitis C virus (HCV): Potential role in HCV-related liver cancer.

Benkheil M, Van Haele M, Roskams T, Laporte M, Noppen S, Abbasi K, Delang L, Neyts J, Liekens S.

Exp Cell Res. 2018 Nov 15;372(2):168-177. doi: 10.1016/j.yexcr.2018.09.023. Epub 2018 Oct 2.

PMID:
30287142
3.

PI4KIII inhibitor enviroxime impedes the replication of the hepatitis C virus by inhibiting PI3 kinases.

Delang L, Harak C, Benkheil M, Khan H, Leyssen P, Andrews M, Lohmann V, Neyts J.

J Antimicrob Chemother. 2018 Dec 1;73(12):3375-3384. doi: 10.1093/jac/dky327.

PMID:
30219827
4.

Differential Transmission of Antiviral Drug-Resistant Chikungunya Viruses by Aedes Mosquitoes.

Delang L, Yen PS, Vallet T, Vazeille M, Vignuzzi M, Failloux AB.

mSphere. 2018 Aug 22;3(4). pii: e00230-18. doi: 10.1128/mSphere.00230-18.

5.

Antiplasmodial, anti-chikungunya virus and antioxidant activities of 64 endemic plants from the Mascarene Islands.

Ledoux A, Cao M, Jansen O, Mamede L, Campos PE, Payet B, Clerc P, Grondin I, Girard-Valenciennes E, Hermann T, Litaudon M, Vanderheydt C, Delang L, Neyts J, Leyssen P, Frédérich M, Smadja J.

Int J Antimicrob Agents. 2018 Nov;52(5):622-628. doi: 10.1016/j.ijantimicag.2018.07.017. Epub 2018 Jul 29.

PMID:
30063998
6.

Favipiravir as a potential countermeasure against neglected and emerging RNA viruses.

Delang L, Abdelnabi R, Neyts J.

Antiviral Res. 2018 May;153:85-94. doi: 10.1016/j.antiviral.2018.03.003. Epub 2018 Mar 7. Review.

PMID:
29524445
7.

Rational modifications on a benzylidene-acrylohydrazide antiviral scaffold, synthesis and evaluation of bioactivity against Chikungunya virus.

Giancotti G, Cancellieri M, Balboni A, Giustiniano M, Novellino E, Delang L, Neyts J, Leyssen P, Brancale A, Bassetto M.

Eur J Med Chem. 2018 Apr 10;149:56-68. doi: 10.1016/j.ejmech.2018.02.054. Epub 2018 Feb 23.

PMID:
29499487
8.

Inhibition of the Replication of Different Strains of Chikungunya Virus by 3-Aryl-[1,2,3]triazolo[4,5- d]pyrimidin-7(6 H)-ones.

Gómez-SanJuan A, Gamo AM, Delang L, Pérez-Sánchez A, Amrun SN, Abdelnabi R, Jacobs S, Priego EM, Camarasa MJ, Jochmans D, Leyssen P, Ng LFP, Querat G, Neyts J, Pérez-Pérez MJ.

ACS Infect Dis. 2018 Apr 13;4(4):605-619. doi: 10.1021/acsinfecdis.7b00219. Epub 2018 Feb 14.

PMID:
29406692
9.

Design, synthesis and evaluation against Chikungunya virus of novel small-molecule antiviral agents.

Tardugno R, Giancotti G, De Burghgraeve T, Delang L, Neyts J, Leyssen P, Brancale A, Bassetto M.

Bioorg Med Chem. 2018 Feb 15;26(4):869-874. doi: 10.1016/j.bmc.2018.01.002. Epub 2018 Jan 6.

PMID:
29336951
10.

New class of early-stage enterovirus inhibitors with a novel mechanism of action.

Ma Y, Abdelnabi R, Delang L, Froeyen M, Luyten W, Neyts J, Mirabelli C.

Antiviral Res. 2017 Nov;147:67-74. doi: 10.1016/j.antiviral.2017.10.004. Epub 2017 Oct 7.

PMID:
28993161
11.

Antiviral treatment efficiently inhibits chikungunya virus infection in the joints of mice during the acute but not during the chronic phase of the infection.

Abdelnabi R, Jochmans D, Verbeken E, Neyts J, Delang L.

Antiviral Res. 2018 Jan;149:113-117. doi: 10.1016/j.antiviral.2017.09.016. Epub 2017 Sep 25.

PMID:
28958920
12.

Replication of the Zika virus in different iPSC-derived neuronal cells and implications to assess efficacy of antivirals.

Lanko K, Eggermont K, Patel A, Kaptein S, Delang L, Verfaillie CM, Neyts J.

Antiviral Res. 2017 Sep;145:82-86. doi: 10.1016/j.antiviral.2017.07.010. Epub 2017 Jul 20.

13.

Antiviral activity of [1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones against chikungunya virus targeting the viral capping nsP1.

Gigante A, Gómez-SanJuan A, Delang L, Li C, Bueno O, Gamo AM, Priego EM, Camarasa MJ, Jochmans D, Leyssen P, Decroly E, Coutard B, Querat G, Neyts J, Pérez-Pérez MJ.

Antiviral Res. 2017 Aug;144:216-222. doi: 10.1016/j.antiviral.2017.06.003. Epub 2017 Jun 12.

14.

Chikungunya virus infections: time to act, time to treat.

Abdelnabi R, Neyts J, Delang L.

Curr Opin Virol. 2017 Jun;24:25-30. doi: 10.1016/j.coviro.2017.03.016. Epub 2017 Apr 14. Review.

PMID:
28414993
15.

Understanding the Mechanism of the Broad-Spectrum Antiviral Activity of Favipiravir (T-705): Key Role of the F1 Motif of the Viral Polymerase.

Abdelnabi R, Morais ATS, Leyssen P, Imbert I, Beaucourt S, Blanc H, Froeyen M, Vignuzzi M, Canard B, Neyts J, Delang L.

J Virol. 2017 May 26;91(12). pii: e00487-17. doi: 10.1128/JVI.00487-17. Print 2017 Jun 15.

16.

Glutathione is a highly efficient thermostabilizer of poliovirus Sabin strains.

Abdelnabi R, Delang L, Neyts J.

Vaccine. 2017 Mar 7;35(10):1370-1372. doi: 10.1016/j.vaccine.2017.01.070. Epub 2017 Feb 8.

PMID:
28189401
17.

Discovery of Multitarget Agents Active as Broad-Spectrum Antivirals and Correctors of Cystic Fibrosis Transmembrane Conductance Regulator for Associated Pulmonary Diseases.

Tassini S, Sun L, Lanko K, Crespan E, Langron E, Falchi F, Kissova M, Armijos-Rivera JI, Delang L, Mirabelli C, Neyts J, Pieroni M, Cavalli A, Costantino G, Maga G, Vergani P, Leyssen P, Radi M.

J Med Chem. 2017 Feb 23;60(4):1400-1416. doi: 10.1021/acs.jmedchem.6b01521. Epub 2017 Feb 10.

PMID:
28122178
18.

Uncovering oxysterol-binding protein (OSBP) as a target of the anti-enteroviral compound TTP-8307.

Albulescu L, Bigay J, Biswas B, Weber-Boyvat M, Dorobantu CM, Delang L, van der Schaar HM, Jung YS, Neyts J, Olkkonen VM, van Kuppeveld FJM, Strating JRPM.

Antiviral Res. 2017 Apr;140:37-44. doi: 10.1016/j.antiviral.2017.01.008. Epub 2017 Jan 11.

19.

Protein kinases C as potential host targets for the inhibition of chikungunya virus replication.

Abdelnabi R, Amrun SN, Ng LF, Leyssen P, Neyts J, Delang L.

Antiviral Res. 2017 Mar;139:79-87. doi: 10.1016/j.antiviral.2016.12.020. Epub 2016 Dec 27.

PMID:
28039020
20.

Discovery of novel multi-target indole-based derivatives as potent and selective inhibitors of chikungunya virus replication.

Scuotto M, Abdelnabi R, Collarile S, Schiraldi C, Delang L, Massa A, Ferla S, Brancale A, Leyssen P, Neyts J, Filosa R.

Bioorg Med Chem. 2017 Jan 1;25(1):327-337. doi: 10.1016/j.bmc.2016.10.037. Epub 2016 Oct 31.

PMID:
27856239
21.

Comparative analysis of the anti-chikungunya virus activity of novel bryostatin analogs confirms the existence of a PKC-independent mechanism.

Abdelnabi R, Staveness D, Near KE, Wender PA, Delang L, Neyts J, Leyssen P.

Biochem Pharmacol. 2016 Nov 15;120:15-21. doi: 10.1016/j.bcp.2016.09.020. Epub 2016 Sep 21.

22.

The viral capping enzyme nsP1: a novel target for the inhibition of chikungunya virus infection.

Delang L, Li C, Tas A, Quérat G, Albulescu IC, De Burghgraeve T, Guerrero NA, Gigante A, Piorkowski G, Decroly E, Jochmans D, Canard B, Snijder EJ, Pérez-Pérez MJ, van Hemert MJ, Coutard B, Leyssen P, Neyts J.

Sci Rep. 2016 Aug 22;6:31819. doi: 10.1038/srep31819.

23.

Optimization of a Class of Tryptophan Dendrimers That Inhibit HIV Replication Leads to a Selective, Specific, and Low-Nanomolar Inhibitor of Clinical Isolates of Enterovirus A71.

Rivero-Buceta E, Sun L, Martínez-Gualda B, Doyagüez EG, Donckers K, Quesada E, Camarasa MJ, Delang L, San-Félix A, Neyts J, Leyssen P.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):5064-7. doi: 10.1128/AAC.00626-16. Print 2016 Aug.

24.

Antiviral Strategies Against Chikungunya Virus.

Abdelnabi R, Neyts J, Delang L.

Methods Mol Biol. 2016;1426:243-53. doi: 10.1007/978-1-4939-3618-2_22.

PMID:
27233277
25.

Inhibition of Chikungunya Virus-Induced Cell Death by Salicylate-Derived Bryostatin Analogues Provides Additional Evidence for a PKC-Independent Pathway.

Staveness D, Abdelnabi R, Near KE, Nakagawa Y, Neyts J, Delang L, Leyssen P, Wender PA.

J Nat Prod. 2016 Apr 22;79(4):680-4. doi: 10.1021/acs.jnatprod.5b01017. Epub 2016 Feb 22.

26.

Simplified Bryostatin Analogues Protect Cells from Chikungunya Virus-Induced Cell Death.

Staveness D, Abdelnabi R, Schrier AJ, Loy BA, Verma VA, DeChristopher BA, Near KE, Neyts J, Delang L, Leyssen P, Wender PA.

J Nat Prod. 2016 Apr 22;79(4):675-9. doi: 10.1021/acs.jnatprod.5b01016. Epub 2016 Feb 22.

27.

Exploring the importance of zinc binding and steric/hydrophobic factors in novel HCV replication inhibitors.

Talley DC, Delang L, Neyts J, Leyssen P, Smith PJ.

Bioorg Med Chem Lett. 2016 Feb 15;26(4):1196-9. doi: 10.1016/j.bmcl.2016.01.035. Epub 2016 Jan 16.

PMID:
26804234
28.

The future of antivirals: broad-spectrum inhibitors.

Debing Y, Neyts J, Delang L.

Curr Opin Infect Dis. 2015 Dec;28(6):596-602. doi: 10.1097/QCO.0000000000000212. Review.

PMID:
26524332
29.

Antiviral Activity of Broad-Spectrum and Enterovirus-Specific Inhibitors against Clinical Isolates of Enterovirus D68.

Sun L, Meijer A, Froeyen M, Zhang L, Thibaut HJ, Baggen J, George S, Vernachio J, van Kuppeveld FJ, Leyssen P, Hilgenfeld R, Neyts J, Delang L.

Antimicrob Agents Chemother. 2015 Dec;59(12):7782-5. doi: 10.1128/AAC.01375-15. Epub 2015 Sep 14.

30.

Towards antivirals against chikungunya virus.

Abdelnabi R, Neyts J, Delang L.

Antiviral Res. 2015 Sep;121:59-68. doi: 10.1016/j.antiviral.2015.06.017. Epub 2015 Jun 25. Review.

PMID:
26119058
31.

Understanding the molecular mechanism of host-based statin resistance in hepatitis C virus replicon containing cells.

Delang L, Scheers E, Grabner M, Verpaalen B, Helsen N, Vanstreels E, Daelemans D, Verfaillie C, Neyts J.

Biochem Pharmacol. 2015 Aug 1;96(3):190-201. doi: 10.1016/j.bcp.2015.06.003. Epub 2015 Jun 9.

PMID:
26070251
32.

Antiviral Activity of Diterpene Esters on Chikungunya Virus and HIV Replication.

Nothias-Scaglia LF, Pannecouque C, Renucci F, Delang L, Neyts J, Roussi F, Costa J, Leyssen P, Litaudon M, Paolini J.

J Nat Prod. 2015 Jun 26;78(6):1277-83. doi: 10.1021/acs.jnatprod.5b00073. Epub 2015 May 13.

PMID:
25970561
33.

Itraconazole inhibits enterovirus replication by targeting the oxysterol-binding protein.

Strating JR, van der Linden L, Albulescu L, Bigay J, Arita M, Delang L, Leyssen P, van der Schaar HM, Lanke KH, Thibaut HJ, Ulferts R, Drin G, Schlinck N, Wubbolts RW, Sever N, Head SA, Liu JO, Beachy PA, De Matteis MA, Shair MD, Olkkonen VM, Neyts J, van Kuppeveld FJ.

Cell Rep. 2015 Feb 3;10(4):600-15. doi: 10.1016/j.celrep.2014.12.054. Epub 2015 Jan 29.

34.

Structure-activity relationship study of arbidol derivatives as inhibitors of chikungunya virus replication.

Di Mola A, Peduto A, La Gatta A, Delang L, Pastorino B, Neyts J, Leyssen P, de Rosa M, Filosa R.

Bioorg Med Chem. 2014 Nov 1;22(21):6014-25. doi: 10.1016/j.bmc.2014.09.013. Epub 2014 Sep 16.

PMID:
25282648
35.

Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral.

Delang L, Segura Guerrero N, Tas A, Quérat G, Pastorino B, Froeyen M, Dallmeier K, Jochmans D, Herdewijn P, Bello F, Snijder EJ, de Lamballerie X, Martina B, Neyts J, van Hemert MJ, Leyssen P.

J Antimicrob Chemother. 2014 Oct;69(10):2770-84. doi: 10.1093/jac/dku209. Epub 2014 Jun 20.

PMID:
24951535
36.

Tigliane diterpenes from Croton mauritianus as inhibitors of chikungunya virus replication.

Corlay N, Delang L, Girard-Valenciennes E, Neyts J, Clerc P, Smadja J, Guéritte F, Leyssen P, Litaudon M.

Fitoterapia. 2014 Sep;97:87-91. doi: 10.1016/j.fitote.2014.05.015. Epub 2014 May 28.

PMID:
24879904
37.

Identification of [1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones as novel inhibitors of Chikungunya virus replication.

Gigante A, Canela MD, Delang L, Priego EM, Camarasa MJ, Querat G, Neyts J, Leyssen P, Pérez-Pérez MJ.

J Med Chem. 2014 May 22;57(10):4000-8. doi: 10.1021/jm401844c. Epub 2014 May 6.

PMID:
24800626
38.

Are statins a viable option for the treatment of infections with the hepatitis C virus?

Verpaalen B, Neyts J, Delang L.

Antiviral Res. 2014 May;105:92-9. doi: 10.1016/j.antiviral.2014.02.020. Epub 2014 Mar 6.

PMID:
24613180
39.

Selecting and characterizing drug-resistant hepatitis C virus replicon.

Vliegen I, Delang L, Neyts J.

Methods Mol Biol. 2013;1030:93-103. doi: 10.1007/978-1-62703-484-5_8.

PMID:
23821262
40.

Hepatitis C virus-specific directly acting antiviral drugs.

Delang L, Neyts J, Vliegen I, Abrignani S, Neddermann P, De Francesco R.

Curr Top Microbiol Immunol. 2013;369:289-320. doi: 10.1007/978-3-642-27340-7_12. Review.

PMID:
23463206
41.

Computer-aided identification, design and synthesis of a novel series of compounds with selective antiviral activity against chikungunya virus.

Bassetto M, De Burghgraeve T, Delang L, Massarotti A, Coluccia A, Zonta N, Gatti V, Colombano G, Sorba G, Silvestri R, Tron GC, Neyts J, Leyssen P, Brancale A.

Antiviral Res. 2013 Apr;98(1):12-8. doi: 10.1016/j.antiviral.2013.01.002. Epub 2013 Feb 1.

PMID:
23380636
42.

Prostratin and 12-O-tetradecanoylphorbol 13-acetate are potent and selective inhibitors of Chikungunya virus replication.

Bourjot M, Delang L, Nguyen VH, Neyts J, Guéritte F, Leyssen P, Litaudon M.

J Nat Prod. 2012 Dec 28;75(12):2183-7. doi: 10.1021/np300637t. Epub 2012 Dec 7.

PMID:
23215460
43.

The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination.

Zahid MN, Turek M, Xiao F, Thi VL, Guérin M, Fofana I, Bachellier P, Thompson J, Delang L, Neyts J, Bankwitz D, Pietschmann T, Dreux M, Cosset FL, Grunert F, Baumert TF, Zeisel MB.

Hepatology. 2013 Feb;57(2):492-504. doi: 10.1002/hep.26097. Epub 2012 Dec 28.

44.

The role of phosphatidylinositol 4-kinases and phosphatidylinositol 4-phosphate during viral replication.

Delang L, Paeshuyse J, Neyts J.

Biochem Pharmacol. 2012 Dec 1;84(11):1400-8. doi: 10.1016/j.bcp.2012.07.034. Epub 2012 Aug 8. Review.

PMID:
22885339
45.

Identification of a novel resistance mutation for benzimidazole inhibitors of the HCV RNA-dependent RNA polymerase.

Delang L, Froeyen M, Herdewijn P, Neyts J.

Antiviral Res. 2012 Jan;93(1):30-8. doi: 10.1016/j.antiviral.2011.10.012. Epub 2011 Oct 19.

PMID:
22033247
46.

Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication.

Delang L, Vliegen I, Froeyen M, Neyts J.

Antimicrob Agents Chemother. 2011 Sep;55(9):4103-13. doi: 10.1128/AAC.00294-11. Epub 2011 Jun 27.

47.

In vitro selection and characterization of HCV replicons resistant to multiple non-nucleoside polymerase inhibitors.

Delang L, Vliegen I, Leyssen P, Neyts J.

J Hepatol. 2012 Jan;56(1):41-8. doi: 10.1016/j.jhep.2011.04.016. Epub 2011 May 20.

PMID:
21703175
48.

Antiviral therapy for hepatitis C virus: beyond the standard of care.

Delang L, Coelmont L, Neyts J.

Viruses. 2010 Apr;2(4):826-66. doi: 10.3390/v2040826. Epub 2010 Mar 29.

49.

Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development.

Delang L, Paeshuyse J, Vliegen I, Leyssen P, Obeid S, Durantel D, Zoulim F, Op de Beeck A, Neyts J.

Hepatology. 2009 Jul;50(1):6-16. doi: 10.1002/hep.22916.

PMID:
19437494

Supplemental Content

Loading ...
Support Center